TGF-Beta inhibits the in vitro induction of lymphokine-activated killing activity

[1]  D. Rush,et al.  Inhibition of cytokine production by cyclosporine A and G. , 1989, Transplantation.

[2]  L. Owen-Schaub,et al.  Lymphokine‐Activated Killer Cells , 1988, Annals of the New York Academy of Sciences.

[3]  W. Chan,et al.  The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Frei,et al.  T cell suppressor factor from human glioblastoma cells is a 12.5‐kd protein closely related to transforming growth factor‐beta. , 1987, The EMBO journal.

[5]  F. Robertson,et al.  Characterization of an immunosuppressive factor derived from colon cancer cells. , 1987, Journal of immunology.

[6]  E. Grimm.  Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality. , 1986, Biochimica et biophysica acta.

[7]  M. Sporn,et al.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. , 1986, Journal of immunology.

[8]  A. Chang,et al.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. , 1986, JAMA.

[9]  N. Damle,et al.  Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. , 1986, Journal of immunology.

[10]  J. Ortaldo,et al.  Lymphokine-activated killer cells. Analysis of progenitors and effectors , 1986, The Journal of experimental medicine.

[11]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[12]  M. Sporn,et al.  Transforming growth factor-beta: biological function and chemical structure. , 1986, Science.

[13]  M. Sporn,et al.  Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. , 1986, Journal of immunology.

[14]  M. Sporn,et al.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth , 1986, The Journal of experimental medicine.

[15]  S. Miescher,et al.  Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. , 1986, Journal of immunology.

[16]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[17]  D. Nelson,et al.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.

[18]  Anita B. Roberts,et al.  Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells , 1985, Nature.

[19]  C. Balch,et al.  Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells. , 1985, Cancer research.

[20]  L. Muul,et al.  THE DIFFERENTIAL INHIBITORY EFFECTS EXERTED BY CYCLOSPORINE AND HYDROCORTISONE ON THE ACTIVATION OF HUMAN CYTOTOXIC LYMPHOCYTES BY RECOMBINANT INTERLEUKIN‐2 VERSUS ALLOSPECIFIC CTL , 1985, Transplantation.

[21]  M. Sporn,et al.  Increased secretion of type beta transforming growth factor accompanies viral transformation of cells , 1985, Molecular and cellular biology.

[22]  M. Doyle,et al.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli. , 1984, Science.

[23]  E. Neuwelt,et al.  Presence of immunosuppressive factors in brain-tumor cyst fluid. , 1983, Journal of neurosurgery.

[24]  M. Sporn,et al.  Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Roth,et al.  Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells , 1983, The Journal of experimental medicine.

[26]  M. Sporn,et al.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. , 1983, The Journal of biological chemistry.

[27]  C. B. Childs,et al.  Serum contains a platelet-derived transforming growth factor. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[29]  J. Roth,et al.  Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. , 1982, Journal of immunology.

[30]  E. Uzgiris,et al.  Oscillation of cell surface charge of human peripheral blood lymphocytes after stimulation with concanavalin A. , 1982, Journal of immunology.

[31]  M. Sporn,et al.  New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Barondess.  Book ReviewClinical Examination Bedside Diagnosis , 1980 .

[33]  I. Hellstrom,et al.  Enhancement of tumor outgrowth by tumor‐associated blocking factors , 1979, International journal of cancer.

[34]  M. Netsky,et al.  DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS , 1972, The Journal of experimental medicine.

[35]  L. Owen-Schaub,et al.  Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors. , 1988, Cellular immunology.

[36]  J. Plate,et al.  Cytotoxic T cells : biology and relevance to disease , 1988 .

[37]  S. Jacobs,et al.  In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. , 1986, Journal of neurosurgery.